The retinal microenvironment in diabetic retinopathy

糖尿病视网膜病变的视网膜微环境

基本信息

  • 批准号:
    8316113
  • 负责人:
  • 金额:
    $ 36.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-01 至 2016-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Diabetic retinopathy is one of the most common causes of retinal disease in adults. Many molecular and histological changes have been demonstrated, and it is now recognized that neural as well as vascular problems exist. The most important contributor to vascular dysfunction is the elevation of vascular endothelial growth factor (VEGF), which causes vascular leakage and angiogenesis. Unfortunately, we still do not know what underlies the increase in VEGF. Hypoxia and acidosis are both known regulators of VEGF, but the magnitude and time course of changes in retinal oxygen and pH are not known in diabetes. More information about these parameters will allow a better understanding of disease progression, and ultimately may lead to an understanding of pathways that can be targeted before VEGF causes damage. We will make intraretinal recordings of PO2 and pH in rats with streptozotocin (STZ)-induced diabetes, and in rats with acidosis in the absence of diabetes. To place these changes in the context of other events, we will also measure important vascular parameters (blood flow, leakage, molecular signals). SPECIFIC AIM 1: Oxygen in diabetic retinopathy. Retinal tissue hypoxia has been implicated in the increased VEGF that is found in both the background and proliferative phases of retinopathy. There is considerable indirect support for the existence of hypoxia in diabetic retinopathy, but very limited direct evidence. We will characterize intraretinal oxygenation in rats with up to 1 year of diabetes. Our hypothesis is that inner retinal PO2 will decrease over this time. We will also investigate changes in the regulation of retinal oxygen in diabetics. Our hypothesis is that changes in regulation of PO2 will be a more sensitive indicator of changes in the microenvironment and occur earlier than changes in baseline PO2. We found increased PO2 in the retina in an earlier study at 12 weeks of diabetes. Our hypothesis is that this was due to increased blood flow, which we will now investigate. SPECIFIC AIM 2: Acidosis in diabetic retinopathy. VEGF is regulated by acidosis in some tissues but the role of pH in controlling VEGF in the adult retina is unknown. We will characterize retinal pH in rats with up to 1 year of diabetes. Our hypothesis is that the inner retina will be more acidic than normal for at least a few months. We also hypothesize that molecular mechanisms come into play to reduce acidosis, such as increased carbonic anhydrase and acid removal mechanisms. These will be evaluated with mRNA and protein measurements. SPECIFIC AIM 3: Is retinal acidosis sufficient to upregulate VEGF? Finding that the diabetic retina is acidotic will open the possibility that it is one of the factors that regulates VEGF, but will not tell us whether it is important. Consequently, we will produce acidosis in the absence of diabetes, via carbonic anhydrase inhibition. We will first establish a treatment protocol that yields intraretinal pH values similar to diabetes, and then evaluate changes in VEGF and leakage. Our hypothesis is that acidosis alone will be sufficient to increase VEGF, produce molecular changes that underlie leakage, and cause leakage itself.
描述(由申请人提供):糖尿病性视网膜病是成人视网膜疾病最常见的原因之一。已经证明了许多分子和组织学变化,现在已经认识到存在神经和血管问题。引起血管功能障碍的最重要的因素是血管内皮生长因子(VEGF)的升高,这会导致血管泄漏和血管生成。不幸的是,我们仍然不知道是什么是VEGF增加的基础。缺氧和酸中毒都是VEGF的已知调节剂,但是视网膜氧和pH的变化的大小和时间过程在糖尿病中尚不清楚。有关这些参数的更多信息将使人们更好地了解疾病的进展,最终可能会导致对可以在VEGF造成损害之前的途径的理解。我们将在患有链蛋白酶(STZ)诱导的糖尿病的大鼠中对PO2和pH的视网膜内记录,在没有糖尿病的情况下患有酸中毒的大鼠。为了将这些变化放在其他事件的背景下,我们还将测量重要的血管参数(血流,泄漏,分子信号)。特定目标1:糖尿病性视网膜病中的氧气。视网膜组织缺氧与视网膜病的背景和增殖阶段发现的VEGF有关。对于糖尿病性视网膜病中缺氧的存在,有相当大的间接支持,但直接证据非常有限。我们将表征最多1年糖尿病的大鼠的内部氧合。我们的假设是内部视网膜PO2将在这段时间内减少。我们还将研究糖尿病患者视网膜氧气调节的变化。我们的假设是,PO2调节的变化将是微环境变化的更敏感的指标,并且比基线PO2的变化更早。我们发现,在糖尿病12周的早期研究中,视网膜中的PO2增加了。我们的假设是,这是由于血流增加所致,我们现在将调查。特定目标2:糖尿病性视网膜病中的酸中毒。 VEGF受某些组织中的酸中毒调节,但是pH在控制成人视网膜中VEGF中的作用尚不清楚。我们将表征患有长达1年糖尿病的大鼠的视网膜pH值。我们的假设是,内部视网膜至少几个月将比正常情况更酸性。我们还假设分子机制可以减少酸中毒,例如增加的碳酸酐酶和酸去除机制。这些将通过mRNA和蛋白质测量进行评估。特定目标3:视网膜酸中毒足以上调VEGF?发现糖尿病性视网膜是酸性的,它将打开它是调节VEGF的因素之一,但不会告诉我们它是否重要。因此,我们将在没有糖尿病的情况下通过碳酸酐酶抑制产生酸中毒。我们将首先建立一种治疗方案,该方案产生类似于糖尿病的视网膜内pH值,然后评估VEGF和泄漏的变化。我们的假设是,仅酸中毒就足以增加VEGF,产生渗漏构成并引起泄漏本身的分子变化。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT A. LINSENMEIER其他文献

ROBERT A. LINSENMEIER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT A. LINSENMEIER', 18)}}的其他基金

Spatially resolved measurements of retinal metabolism
视网膜代谢的空间分辨测量
  • 批准号:
    10153785
  • 财政年份:
    2019
  • 资助金额:
    $ 36.75万
  • 项目类别:
Spatially resolved measurements of retinal metabolism
视网膜代谢的空间分辨测量
  • 批准号:
    9906901
  • 财政年份:
    2019
  • 资助金额:
    $ 36.75万
  • 项目类别:
A clinically applicable model of retinal oxygen metabolism
临床适用的视网膜氧代谢模型
  • 批准号:
    9227475
  • 财政年份:
    2017
  • 资助金额:
    $ 36.75万
  • 项目类别:
The retinal microenvironment in diabetic retinopathy
糖尿病视网膜病变的视网膜微环境
  • 批准号:
    8723217
  • 财政年份:
    2011
  • 资助金额:
    $ 36.75万
  • 项目类别:
The retinal microenvironment in diabetic retinopathy
糖尿病视网膜病变的视网膜微环境
  • 批准号:
    8187702
  • 财政年份:
    2011
  • 资助金额:
    $ 36.75万
  • 项目类别:
The retinal microenvironment in diabetic retinopathy
糖尿病视网膜病变的视网膜微环境
  • 批准号:
    8531256
  • 财政年份:
    2011
  • 资助金额:
    $ 36.75万
  • 项目类别:
The retinal microenvironment in diabetic retinopathy
糖尿病视网膜病变的视网膜微环境
  • 批准号:
    8916116
  • 财政年份:
    2011
  • 资助金额:
    $ 36.75万
  • 项目类别:
Third Biomedical Engineering Education Summit Meeting
第三届生物医学工程教育高峰会议
  • 批准号:
    7484902
  • 财政年份:
    2008
  • 资助金额:
    $ 36.75万
  • 项目类别:
MICROENVIRONMENT OF THE RETINA
视网膜微环境
  • 批准号:
    2888150
  • 财政年份:
    1983
  • 资助金额:
    $ 36.75万
  • 项目类别:
MICROENVIRONMENT OF THE RETINA
视网膜微环境
  • 批准号:
    2159232
  • 财政年份:
    1983
  • 资助金额:
    $ 36.75万
  • 项目类别:

相似国自然基金

去泛素化酶USP5调控P53通路在伴E2A-PBX1成人ALL的致病机制研究
  • 批准号:
    81900151
  • 批准年份:
    2019
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
核基质结合区蛋白SATB1调控CCR7抑制急性T淋巴细胞白血病中枢浸润的作用与机制
  • 批准号:
    81870113
  • 批准年份:
    2018
  • 资助金额:
    55.0 万元
  • 项目类别:
    面上项目
成人及儿童急性淋巴细胞白血病的基因组转录组生物信息学分析方法建立及数据分析
  • 批准号:
    81570122
  • 批准年份:
    2015
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目
NR3C1基因突变在成人急性淋巴细胞白血病耐药与复发中的作用与机制研究
  • 批准号:
    81470309
  • 批准年份:
    2014
  • 资助金额:
    75.0 万元
  • 项目类别:
    面上项目
儿童和成人急性T淋巴细胞白血病中miRNA和转录因子共调控网络的差异性研究
  • 批准号:
    31270885
  • 批准年份:
    2012
  • 资助金额:
    80.0 万元
  • 项目类别:
    面上项目

相似海外基金

The regulation of renal tubular transport by cannabinoid receptor type 1 (CB1R) and its endogenous lipid ligands
1型大麻素受体(CB1R)及其内源性脂质配体对肾小管转运的调节
  • 批准号:
    10588113
  • 财政年份:
    2023
  • 资助金额:
    $ 36.75万
  • 项目类别:
A Randomized Clinical Trial of the Safety and FeasibiLity of Metformin as a Treatment for sepsis induced AKI (LiMiT AKI)
二甲双胍治疗脓毒症引起的 AKI (LiMiT AKI) 的安全性和可行性的随机临床试验
  • 批准号:
    10656829
  • 财政年份:
    2023
  • 资助金额:
    $ 36.75万
  • 项目类别:
A Multiplex Analyzer for Sepsis Management
用于脓毒症管理的多重分析仪
  • 批准号:
    10483277
  • 财政年份:
    2022
  • 资助金额:
    $ 36.75万
  • 项目类别:
Kidney Support in Pediatric Patients Using an Ultrafiltration Device
使用超滤装置为儿科患者提供肾脏支持
  • 批准号:
    10407077
  • 财政年份:
    2021
  • 资助金额:
    $ 36.75万
  • 项目类别:
Kidney Support in Pediatric Patients Using an Ultrafiltration Device
使用超滤装置为儿科患者提供肾脏支持
  • 批准号:
    10620178
  • 财政年份:
    2021
  • 资助金额:
    $ 36.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了